Application of an algorithm to analyze patterns of intermittent oral corticosteroid use in asthma

Competing interests

The Authors declare no Competing Non-Financial Interests but the following Competing Financial Interests: J.H. reports personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, Circassia and Teva unrelated to the conduct of the study. D.P., D.S., H.H., J.S.K.C. and V.C. are employees of the Observational and Pragmatic Research Institute, which received funding from AstraZeneca to conduct this study. A.B. has received consultancy fees and speakers’ fees from AstraZeneca, Amgen, Boehringer Ingelheim, Novartis, GlaxoSmithKline, Sanofi and Chiesi, and research grants from GlaxoSmithKline, Boehringer Ingelheim and AstraZeneca. A.M.G. has received grants, advisory board fees, lecture fees, and consulting fees from AstraZeneca; advisory board fees from GlaxoSmithKline; advisory board fees and lecture fees from Novartis; advisory board fees from Regeneron; advisory board fees, lecture fees and travel expenses from Teva; advisory board fees, lecture fees and consulting fees from Sanofi. D.P. has advisory board membership with AstraZeneca, Boehringer Ingelheim, Chiesi, Mylan, Novartis, Regeneron Pharmaceuticals, Sanofi, Thermofisher; consultancy agreements with Airway Vista Secretariat, AstraZeneca, Boehringer Ingelheim, Chiesi, EPG Communication Holdings Ltd, FIECON Ltd, Fieldwork International, GlaxoSmithKline, Mylan, Mundipharma, Novartis, OM Pharma SA, PeerVoice, Phadia AB, Spirosure Inc, Strategic North Limited, Synapse Research Management Partners S.L., Talos Health Solutions, Theravance and WebMD Global LLC; grants and unrestricted funding for investigator-initiated studies (conducted through Observational and Pragmatic Research Institute Pte Ltd) from AstraZeneca, Boehringer Ingelheim, Chiesi, Mylan, Novartis, Regeneron Pharmaceuticals, Respiratory Effectiveness Group, Sanofi, Theravance and UK National Health Service; payment for lectures/speaking engagements from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GlaxoSmithKline, Kyorin, Mylan, Mundipharma, Novartis, Regeneron Pharmaceuticals and Sanofi; payment for travel/accommodation/meeting expenses from AstraZeneca, Boehringer Ingelheim, Mundipharma, Mylan, Novartis and Thermofisher; stock/stock options from AKL Research and Development Ltd which produces phytopharmaceuticals; owns 74% of the social enterprise Optimum Patient Care Ltd (Australia and UK) and 92.61% of Observational and Pragmatic Research Institute Pte Ltd (Singapore); 5% shareholding in Timestamp which develops adherence monitoring technology; is peer reviewer for grant committees of the UK Efficacy and Mechanism Evaluation program, and Health Technology Assessment; and was an expert witness for GlaxoSmithKline. D.J.J. has received consultancy fees and speakers’ fees from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Sanofi and Chiesi, and research grants from AstraZeneca. J.C., E.M. and T.N.T. are employees of AstraZeneca and hold shares in the company.

留言 (0)

沒有登入
gif